



Your Contact

Gangolf Schrimpf +49 6151 72-9591
Investor Relations +49 6151 72-3321

News Release

February 20, 2014

Merck KGaA, Darmstadt, Germany, Appoints Simon Sturge as New Head of Biosimilars Unit

Darmstadt, Germany, February 20, 2014 – Merck KGaA, Darmstadt, Germany, announced today that Simon Sturge (54) will join the company from Boehringer Ingelheim effective March 1, 2014, to head the biosimilars unit. In his new role Sturge will report to Stefan Oschmann, Member of the company's Executive Board and responsible for the company's pharmaceutical businesses.

The biosimilars unit is part of the pharmaceutical businesses of Merck KGaA, Darmstadt, Germany, alongside with the biopharmaceuticals division, Consumer Health and Allergopharma. Early 2012 Merck KGaA, Darmstadt, Germany, decided to set up the biosimilars unit to develop molecules for oncology and inflammatory disorders through in-house research & development expertise in biologics as well as partnerships with other biosimilars players, such as Dr. Reddy's Laboratories. The unit is located in Canton de Vaud, Switzerland, where it makes use of the company's state-of-the-art biologics manufacturing facilities of Aubonne and Corsier sur Vevey with support from other European sites of the company. With its investments in the evolving biosimilars market, Merck KGaA, Darmstadt, Germany, expects to benefit from rising demand for biotechnology solutions to address unmet medical needs and transform patients' lives with innovative specialty medicines.

"We have all the capabilities to compete in biosimilars and we expect significant growth of this market by the end of the decade," said Stefan Oschmann. "Simon Sturge is ideally suited to develop our biosimilars unit and to be among the important players in this field."

Page 1 of 3

Merck KGaA

Frankfurter Strasse 250
64293 Darmstadt, Germany
Hotline +49 (0) 6151 72-5000
www.emdgroup.com

Head Media Relations -62445
Spokesperson: -9591 / -7144 / -6328
Fax +49 (0) 6151 72-3138
media.relations@emdgroup.com



News Release

Sturge joins from Boehringer Ingelheim where he as Head of Biopharmaceuticals (including Biosimilars) reported to the Board of the company. Prior to Boehringer Ingelheim Sturge was CEO of Dutch biotech-company OctoPlus NV and before that position he acted as CEO of Vernalis. Sturge also held several roles of increasing seniority from Business Development, Marketing, Operations to CEO at Lonza Biologics, at Celltech Biologics, and at Astra.

Sturge, a British native, holds a BSc Hons in Biology from the University of Sussex in the U.K. He was awarded UK Mediscience CEO of the year in 2005.

Sturge succeeds Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the biopharmaceuticals division at the end of last year.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical, chemical and life science company with total revenues of € 11.2 billion in 2012, a history that began in 1668, and a future shaped by approx. 38,000 employees in 66 countries. Its success is characterized by innovations from entrepreneurial employees. The company's operating activities come under the umbrella of Merck KGaA, Darmstadt, Germany, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Worldwide there are two separate companies that bear the name "Merck", the original Merck KGaA from Darmstadt, Germany, the oldest pharmaceutical and chemical company in the world, and the pharmaceutical company Merck & Co. in the United States. The rights to the name and trademark MERCK in North America (USA and Canada) lie with Merck & Co., the former U.S. subsidiary, whereas Merck KGaA, Darmstadt, Germany, operates in North America under the umbrella brand EMD. In the rest of the



Merck KGaA
Darmstadt · Germany

News Release

world, Merck KGaA, Darmstadt, Germany, owns the rights to the Merck name and trademark. This press release was distributed by Merck KGaA, Darmstadt, Germany.